Title |
Laquinimod for multiple sclerosis
|
---|---|
Published in |
Cochrane database of systematic reviews, August 2013
|
DOI | 10.1002/14651858.cd010475.pub2 |
Pubmed ID | |
Authors |
Dian He, Kai Han, Xiangdong Gao, Shuai Dong, Lan Chu, ZhanHui Feng, Shan Wu |
Abstract |
Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not all MS patients respond adequately to currently available disease-modifying drugs (DMDs). Alternative MS treatments with new modes of action are required to expand the current options for disease-modifying therapies (DMTs) and to aim for freedom from relapses, inflammatory lesions, disability progression and neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection and is a potentially promising new oral DMD in the treatment of relapsing MS. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
South Africa | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 141 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 24 | 17% |
Student > Ph. D. Student | 17 | 12% |
Student > Bachelor | 14 | 10% |
Researcher | 13 | 9% |
Other | 7 | 5% |
Other | 19 | 13% |
Unknown | 50 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 50 | 35% |
Nursing and Health Professions | 14 | 10% |
Psychology | 6 | 4% |
Social Sciences | 3 | 2% |
Biochemistry, Genetics and Molecular Biology | 3 | 2% |
Other | 11 | 8% |
Unknown | 57 | 40% |